{
    "Trade/Device Name(s)": [
        "Access PCT",
        "Access PCT Calibrators",
        "Access PCT Reagent"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K192271",
    "Predicate Device Reference 510(k) Number(s)": [
        "K162827"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PTF"
    ],
    "Summary Letter Date": "November 26, 2019",
    "Summary Letter Received Date": "August 22, 2019",
    "Submission Date": "August 22, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Measure Non-Microbial Analyte(S) In Human Clinical Specimens To Aid In Assessment Of Patients With Suspected Sepsis"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "immunology"
    ],
    "Analyte(s)": [
        "Procalcitonin (PCT)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "Access 2 Immunoassay System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic immunoassay"
    ],
    "Methodologies": [
        "Immunoassay (sandwich principle)"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Access PCT chemiluminescent immunoassay for quantitative determination of procalcitonin in serum and plasma to assess risk of progression to severe sepsis and septic shock.",
    "Indications for Use Summary": "In vitro quantitative determination of procalcitonin (PCT) in human serum and plasma (lithium heparin and EDTA) using Access Immunoassay Systems to aid in risk assessment of critically ill patients for progression to severe sepsis and septic shock.",
    "fda_folder": "Microbiology"
}